Semaglutide May Slow Biological Aging

A new study indicates that semaglutide, a GLP-1 receptor agonist, may influence pathways involved in biological aging and age-related diseases. Researchers analyzed data from a trial involving adults with HIV-associated lipohypertrophy, a condition that can lead to accelerated biological aging. Participants receiving semaglutide showed slower progression in molecular markers of aging compared to a placebo group.

The study, published in Nature Communications, utilized epigenetic clocks to measure biological age. Results revealed that semaglutide-treated individuals experienced slower biological aging in inflammation, brain, and heart measures. This included a 9% reduction in the pace of aging as measured by the DunedinPACE clock and significant improvements in markers linked to mortality risk and age-related disease.

While semaglutide is not a proven anti-aging therapy, these findings suggest potential benefits beyond weight loss, possibly through anti-inflammatory effects and reduction of visceral fat. Further research in larger trials is needed to confirm these effects in broader populations and determine their clinical significance.